Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania
- PMID: 11780879
- DOI: 10.4088/jcp.v62n1210
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania
Abstract
Background: Typical antipsychotics are commonly used in combination with mood stabilizers for acute mania. Although typical antipsychotics are effective, they have undesirable side effects such as induction of depressive symptoms and tardive dyskinesia. Atypical antipsychotics have more favorable side effect profiles, and recent evidence shows their efficacy in treating mania. Apart from a previous small study that compared risperidone with typical neuroleptics as add-on therapy to mood stabilizers, no studies to date have directly compared atypical antipsychotics with typical antipsychotics as add-on therapy to mood stabilizers in a clinically relevant, naturalistic setting.
Method: This study is a chart review of all patients with DSM-IV-defined bipolar disorder, current episode mania (N = 204), admitted to the University of British Columbia Hospital during a 30-month period. Patients were separated into 3 groups according to the medications used: (1) mood stabilizer and typical antipsychotic, (2) mood stabilizer and atypical antipsychotic, and (3) combination: mood stabilizer plus a typical antipsychotic, then switched to mood stabilizer plus risperidone or olanzapine within I week. The atypical group was further subdivided into risperidone and olanzapine subgroups. Outcome was measured using Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement (CGI-I) ratings generated by review of clinical information in the chart.
Results: Patients treated with typical antipsychotics were more severely ill at admission and at discharge than those treated with atypical antipsychotics. Patients in the atypical (p < .005) and combination (p < .05) groups showed significantly greater clinical improvement at discharge than patients treated with typical antipsychotics. This difference was also significant in the subset of patients with psychotic features (p < .03). Risperidone and olanzapine were associated with fewer extrapyramidal side effects than were typical antipsychotics (risperidone vs. typical antipsychotics, chi2 = 8.72, p < .01; olanzapine vs. typical antipsychotics, chi2 = 16.9, p < .001).
Conclusion: Due to their superior effectiveness and side effect profile when compared with typical antipsychotics. atypical antipsychotics are an excellent choice as add-on therapy to mood stabilizers for the treatment of patients with mania.
Similar articles
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting.Int J Neuropsychopharmacol. 2006 Oct;9(5):529-37. doi: 10.1017/S1461145705006073. Epub 2005 Sep 28. Int J Neuropsychopharmacol. 2006. PMID: 16191207
-
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.J Clin Psychiatry. 2000 Sep;61(9):638-42. doi: 10.4088/jcp.v61n0907. J Clin Psychiatry. 2000. PMID: 11030483 Clinical Trial.
-
Use of olanzapine in dysphoric mania.J Affect Disord. 2001 Oct;66(2-3):247-53. doi: 10.1016/s0165-0327(00)00313-x. J Affect Disord. 2001. PMID: 11578678
-
[Treatment of bipolar mania with risperidone].Psychiatr Prax. 2006 Mar;33 Suppl 1:S12-7. doi: 10.1055/s-2005-867024. Psychiatr Prax. 2006. PMID: 16511726 Review. German.
Cited by
-
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.Mol Psychiatry. 2016 Aug;21(8):1050-6. doi: 10.1038/mp.2015.158. Epub 2015 Oct 13. Mol Psychiatry. 2016. PMID: 26460229 Free PMC article. Clinical Trial.
-
Adjunctive treatment of acute mania with risperidone versus typical antipsychotics: a retrospective study.Kaohsiung J Med Sci. 2005 Dec;21(12):539-44. doi: 10.1016/S1607-551X(09)70205-0. Kaohsiung J Med Sci. 2005. PMID: 16670045 Free PMC article.
-
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. Bipolar Disord. 2018. PMID: 29536616 Free PMC article.
-
Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.Clin Drug Investig. 2012 Nov;32(11):747-54. doi: 10.1007/s40261-012-0009-1. Clin Drug Investig. 2012. PMID: 23026845 Clinical Trial.
-
Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights.CNS Drugs. 2007;21(5):367-87. doi: 10.2165/00023210-200721050-00002. CNS Drugs. 2007. PMID: 17447826 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical